Literature DB >> 15110176

TRAIL in the airways.

Noreen M Robertson1, Mary Rosemiller, Rochelle G Lindemeyer, Andrzej Steplewski, James G Zangrilli, Gerald Litwack.   

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is an important immunomodulatory factor that may play a role in the structural changes observed in the asthmatic airways. In vitro as well as in vivo studies have evidenced a dual role for TRAIL: it can either function as a pro- or anti-inflammatory cytokine on inflammatory cells, participating in the initiation and resolution of inflammatory and immune responses. TRAIL is expressed in the airways by inflammatory cells infiltrated in the bronchial mucosa, as well as by structural cells of the airway wall including fibroblasts, epithelial, endothelial, and smooth muscle cells. By releasing TRAIL, these different cell types may then participate in the increased levels of TRAIL observed in bronchoalveolar lavage fluid from asthmatic patients. Taken together, this suggests that TRAIL may play a role in inflammation in asthma. However, concerning its role is dual in the modulation of inflammation, further studies are needed to elucidate the precise role of TRAIL in the airways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110176     DOI: 10.1016/S0083-6729(04)67009-9

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  7 in total

Review 1.  Following the TRAIL to apoptosis.

Authors:  Bharti R Chaudhari; Richard F Murphy; Devendra K Agrawal
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 2.  Alveolar epithelial and endothelial cell apoptosis in emphysema: what we know and what we need to know.

Authors:  Mathieu C Morissette; Julie Parent; Julie Milot
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15

3.  TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.

Authors:  Niklas Finnberg; Andres J P Klein-Szanto; Wafik S El-Deiry
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

4.  DUOX-Mediated Signaling Is Not Required for LPS-Induced Neutrophilic Response in the Airways.

Authors:  Sandra Chang; Angela Linderholm; Richart Harper
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

5.  Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model.

Authors:  Veronica Tisato; Chiara Garrovo; Stefania Biffi; Francesca Petrera; Rebecca Voltan; Fabio Casciano; Germana Meroni; Chiara Agnoletto; Giorgio Zauli; Paola Secchiero
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

6.  Difference of Serum Cytokine Profile in Allergic Asthma Patients According to Disease Severity.

Authors:  Lin Sun; Bo Peng; Jun Zhou; Ping Wang; Yuqing Mo; Guofang Xu; Yi Tao; Hejie Song; Wei Tang; Meiling Jin
Journal:  J Asthma Allergy       Date:  2022-03-06

7.  Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.

Authors:  Yanqiu Wu; Yongchun Shen; Junlong Zhang; Chun Wan; Tao Wang; Dan Xu; Ting Yang; Fuqiang Wen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.